98%
921
2 minutes
20
Background: Childhood obesity is a devastating disease process disproportionately affecting minority and low-income populations. Though bariatric surgery leads to durable weight loss and reversal of multiple obesity-related comorbidities, only a small fraction of pediatric patients undergoes the procedure. We sought to identify factors associated with non-completion in a pediatric bariatric surgery program.
Methods: Retrospective review of consecutive patients ≤18-years-old referred to an academic adolescent bariatric surgery program between 2017 and 2022 (n = 20 completers, 40 non-completers) was completed. Demographics and medical and psychosocial histories were summarized by completion status.
Results: Of the 33% (20/60; 85% female, 30% racial minorities) who successfully completed the program, the median age was 16 years [IQR 16, 17]. The median age of non-completers was 16 years [IQR 15, 17] (55% female, 56% racial minorities). Non-completion was associated with male gender (15% of completers vs 45% of non-completers, p = 0.022), neighborhood income <150% poverty level (0 completers vs 17.5% of non-completers, p = 0.047), and presence of environmental or family stressors (22% of completers vs 65% of non-completers, p = 0.008). Though not statistically significant, non-completers tended to be racial minorities (p = 0.054).
Conclusions: Non-completion of the bariatric surgery pathway was more prevalent among male patients from lower-income neighborhoods with significant environmental or family stressors. These patients also tended to be racial and ethnic minorities. The findings underscore the need for further investigation into barriers to pediatric bariatric surgery.
Level Of Evidence: Level III.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jpedsurg.2024.05.012 | DOI Listing |
Osteoporos Int
September 2025
Department of Rheumatology, Univ. Lille, CHU Lille, MABlab ULR 4490, 59000, Lille, France.
Medications like liraglutide 3.0 mg daily (Saxenda®; Novo Nordisk) and semaglutide 2.4 mg weekly (Wegovy®; Novo Nordisk), which are glucagon-like peptide-1 receptor agonists (GLP-1Ra), have been sanctioned for prolonged weight management in people living with obesity (PwO).
View Article and Find Full Text PDFDiabetes Obes Metab
September 2025
Department of Minimally Invasive Surgery, Hernias and Abdominal Wall Surgery, People's Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Clinical Research Center for Gastroesophageal Reflux Disease and Bariatric Metabolic Surgery, Research Institute of General and Minimally Invasive Surgery, Ur
Aims: This randomised controlled trial compared the efficacy of modified laparoscopic sleeve gastrectomy with fundoplication (LSGFD) versus standard laparoscopic sleeve gastrectomy (LSG) in achieving weight loss and alleviating gastroesophageal reflux disease (GERD) in patients with obesity.
Materials And Methods: Eighty patients with obesity (body mass index [BMI] ≥27.5 kg/m with comorbidities or ≥32.
Diabetes Obes Metab
September 2025
Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Cureus
August 2025
Internal Medicine, Combined Military Hospital, Muzaffarabad, PAK.
This systematic review evaluates the comparative effectiveness of bariatric surgery versus medical therapy in managing obese patients with type 2 diabetes mellitus (T2DM). A decade-long literature search from January 2014 to January 2024 identified 10 randomized controlled trials (RCTs) involving diverse populations, interventions, and outcomes. The analysis demonstrates that bariatric procedures, such as Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), and metabolic surgery, consistently outperform medical interventions, including GLP-1 receptor agonists, SGLT2 inhibitors, and intensive lifestyle modifications, in achieving superior glycemic control, weight reduction, and metabolic improvement.
View Article and Find Full Text PDFCureus
August 2025
Department of Internal Medicine, Hamad Medical Corporation, Doha, QAT.
Peroneal neuropathy is a recognized cause for foot drop, typically following trauma, nerve damage, immobilization, or prolonged external pressure. Recently, rapid weight loss after bariatric surgery has been recognised as a potential cause for peroneal neuropathy. This may be due to the loss of protective fat tissue near the peroneal nerve, increasing its susceptibility to compression.
View Article and Find Full Text PDF